Divergent inflammatory and neurology-related protein levels in long COVID following primary and breakthrough SARS-CoV-2 infections

Long COVID is a complex condition where symptoms persist for more than 3 months after SARS-CoV-2 infection and affects an estimated 5-30% of individuals. While persistent inflammation has emerged as an important feature of this condition, it is unclear if immune responses from COVID-19 vaccination or SARS-CoV-2 re-infection exacerbate or mirror the initial inflammatory responses. We quantified 182 inflammatory and neurology-related proteins in plasma using multiplexed affinity proteomics. Plasma samples from the COVID PROFILE cohort conducted in Victoria, Australia, were collected 6-9 months after first infection, but before COVID-19 vaccination from individuals who had recovered from COVID-19 (n = 21) or from individuals with long COVID (n = 12). To establish baseline plasma profiles, protein levels were benchmarked against unvaccinated, SARS-CoV-2 naive individuals (n = 24). In addition, we performed longitudinal analysis in a subset of individuals (n = 34), where paired samples collected 2-4 weeks after a third COVID-19 vaccine dose and after SARS-CoV-2 breakthrough infection were available to assess inflammatory and neurology protein plasma levels after antigen exposure in these contexts. In this cohort Boruta feature selection and lasso regression models identified IL-20, HAGH, NAAA, CLEC10A, LXN, and MCP-1, TRAIL, G-CSF, NBL1, and CCL23 as best discriminating proteins when comparing the long COVID group to groups of either healthy or COVID-19 recovered. Notably, longitudinal analysis indicated differences in the levels of a subset of plasma proteins following primary infection compared to after COVID-19 booster vaccination and breakthrough infection within the groups. These findings suggest that there is an altered immune response outcome primarily observed in individuals with long COVID upon re-exposure. Bansal, Olechnowicz et al. examine levels of inflammatory and neurology-related proteins in individuals with long COVID. They find that vaccination and breakthrough infections are linked to differential plasma levels of a subset of proteins compared to initial infection suggesting an altered immune response outcome upon re-exposure. Long COVID is a condition in which people continue to have symptoms for more than three months after SARS-CoV-2 infection. Ongoing inflammation is thought to contribute to long COVID, but it is unclear whether COVID-19 vaccination or re-infection with SARS-CoV-2 lead to similar, worse or different inflammatory responses compared with the initial infection in people with this condition. We examined blood proteins linked to inflammation and the nervous system to better understand these responses in people with long COVID, individuals that had completely recovered from the first infection and healthy controls. We found that in both long COVID individuals and completely recovered people there were different changes in the level of some immune-related proteins after vaccination or re-infection compared with the response after the original infection suggesting a different immune response from the initial infection upon re-exposure.